Integrated In-Silico Prioritization of Anti-Diabetic Candidates from Helianthus Tuberosus Using Bibliometrics, Target Prediction, Docking, MD, and ADMET Profiling

2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.2174/0118741045449620260721105108
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Introduction/Objective Diabetes mellitus [DM] is a growing global burden associated with cardiovascular, neurological, and metabolic complications. Helianthus tuberosus [Jerusalem artichoke] contains inulin and bioactive phytochemicals that may modulate DM-related pathways. This study aimed to identify and prioritize candidate antidiabetic compounds through an integrated computational pipeline. Methods Bibliometric analysis of Web of Science and Scopus records retrieved in February 2025 mapped research trends and prioritized candidate molecules. Protein targets were predicted using SwissTargetPrediction. Lead compounds underwent molecular docking with AutoDock Vina, 10-ns molecular dynamics simulations in GROMACS, pharmacokinetic and drug-likeness assessment using SwissADME, and toxicity prediction using ProTox-3 and Way2Drug. Results “Fermentation,” “inulin,” and “metabolism” were the most frequent keywords. Six microbiome-derived metabolites generated through inulin fermentation and five plant phytochemicals were compiled. HDAC3, carbonic anhydrases, PTP1B, and EGLN1 emerged as relevant targets. Butyrate-HDAC3 and ferulic acid-CA XII formed stable complexes during molecular dynamics simulations [average RMSD ≤0.3 nm]. Both compounds had SwissADME bioavailability scores of 0.85, although ferulic acid showed suboptimal solubility. ProTox-3 classified butyrate as Toxicity Class 3 [predicted LD50 approximately 91 mg/kg], with possible blood-brain barrier liability; Way2Drug indicated potential multisystem adverse effects at higher exposures. Discussion These findings suggest complementary antidiabetic mechanisms involving microbiome-derived metabolites and plant phytochemicals, but the computational predictions require experimental confirmation. Conclusion Butyrate and ferulic acid were prioritised for mechanism-focused preclinical validation, with attention to butyrate toxicity and ferulic acid formulation.